|5.||Dilated Cardiomyopathy (Cardiomyopathy, Congestive)
|1.||Tribouilloy, Christophe: 10 articles (02/2015 - 08/2010)|
|2.||Cosyns, Bernard: 8 articles (05/2013 - 04/2004)|
|3.||Van Camp, Guy: 8 articles (05/2013 - 04/2004)|
|4.||Rothman, Richard B: 8 articles (11/2010 - 04/2002)|
|5.||Jobic, Yannick: 7 articles (02/2015 - 01/2010)|
|6.||Maréchaux, Sylvestre: 7 articles (02/2015 - 04/2011)|
|7.||Droogmans, Steven: 7 articles (05/2013 - 09/2007)|
|8.||Andréjak, Michel: 6 articles (07/2014 - 08/2010)|
|9.||Baumann, Michael H: 6 articles (05/2009 - 04/2002)|
|10.||Jousilahti, Pekka: 5 articles (08/2015 - 09/2010)|
|1.||Pergolide (Permax)FDA Link
03/01/2012 - "The aim of this study was to determine whether the presence of symptoms would aid in the detection of valvular heart disease (VHD) in those exposed to pergolide. "
08/01/2005 - "Our study suggests that if a cause-effect relationship exists between pergolide and valvular heart disease, it likely occurs at a low but clinically important Incidence and may be associated with dosage."
03/01/2012 - "Valvular heart disease in patients exposed to pergolide: insights from the clinical presentation."
02/15/2009 - "It has been reported that patients on pergolide and carbergoline have an increased risk of developing valvular heart disease. "
11/01/2008 - "Pergolide and valvular heart disease: the lower the better?"
05/01/2013 - "Valvular heart disease in hyperprolactinemic patients treated with low doses of cabergoline."
05/01/2012 - "Seven of the 10 patients treated with cabergoline and diagnosed with heart valve disease were asymptomatic and diagnosed on the basis of an echocardiography performed as a safety measure. "
09/01/2008 - "This prevalence of valvular heart disease after approximately 3 years of cabergoline treatment is no different from that previously reported in normal populations as determined by echocardiography."
09/01/2008 - "Clinically relevant valvular heart disease was present in 12% of patients (nine of 78) vs. 17% of controls (13 of 78) (P = 0.141) and 17% (eight of 47) of patients treated with cabergoline vs. 3% (one of 31) of patients not treated with cabergoline (P = 0.062). "
07/01/2008 - "We experienced 2 patients of valvular heart disease in Parkinson's patients taking cabergoline. "
08/15/2009 - "Natriuretic peptides reflect cardiac stress and may therefore be useful in the management of patients with valvular heart disease. "
03/01/2010 - "The aim of this study was to evaluate the diagnostic utility of natriuretic peptides of type A and B as noninvasive markers in the diagnosis and treatment of congenital and valvular heart disease. "
01/01/2015 - "Clinical Applications of Natriuretic Peptides in Assessment of Valvular Heart Disease."
05/11/2010 - "Natriuretic peptides in common valvular heart disease."
03/01/2010 - "Natriuretic peptides are efficient, non-invasive cardiac markers for facilitating diagnosis, management and treatment of valvular heart disease."
02/01/1999 - "In conclusion, preoperative dobutamine stress echocardiography proved to be very useful for prediction of the postoperative LV function, and myocardial scintigraphy might be indicative of LV function even in valvular heart disease."
12/20/2012 - "Cardiopulmonary function testing and dobutamine stress echocardiography identify exercise intolerance in patients with asymptomatic valvular heart disease beyond stress-test criteria recommended in recent guidelines. "
02/01/1999 - "To assess the left ventricular (LV) function in valvular heart disease, we employed the preoperative dobutamine stress echocardiography and the myocardial scintigraphy. "
02/01/1999 - "Assessment of left ventricular function using dobutamine stress echocardiography and myocardial scintigraphy in valvular heart disease."
08/01/1996 - "Sixteen patients (15 males, 1 female; mean age 63 years, range 45-78) with severe heart failure (NYHA class III = 5; class IV = 11) secondary to ischemic heart disease (8), dilated cardiomyopathy (5) and valvular heart disease (3), were evaluated for eligibility to intermittent Dobutamine (D) treatment. "
05/01/2013 - "60 patients operated with CPB were enrolled in the prospective study to determine the relations between different modes of perfusion and oxygen transport during surgical correction of combined valvular heart disease. "
01/01/2002 - "Oxygen transport, its metabolic maintenance and immune status were studied in 17 patients with congenital valvular heart disease (CVD) having compensated (n = 8, group 1) and decompensated (n = 9, group 2) defects of hemodynamics. "
01/01/2002 - "[Oxygen transport and immune status in patients with congenital valvular heart disease]."
12/01/2000 - "Two of these four patients, died, one of massive hemosputa, and one of heart valve disease, while two had a good outcome, although one of them has since developed respiratory insufficiency and has received oxygen therapy. "
01/01/1990 - "In the group with old myocardial infarction and valvular heart disease, coronary sinus oxygen saturation remained nearly unchanged during pacing. "
|6.||Heparin (Liquaemin)FDA LinkGeneric
10/01/1988 - "For the prevention of systemic embolism associated with prosthetic heart valves or valvular heart disease, the efficacy of heparin has not been established. "
07/01/1991 - "Heparin and warfarin sodium (Coumadin, Panwarfin, Sofarin) are used most often to treat acute and recurrent venous thromboembolic disease, arterial disease, valvular heart disease, and atrial fibrillation. "
11/01/1987 - "In this article, the pharmacology of warfarin and heparin are reviewed, and the clinical applications of these therapies in patients with valvular heart disease, atrial fibrillation, or both, discussed."
03/01/2006 - "A patient with triple heart valve disease, heparin-induced thrombocytopenia, and terminal renal insufficiency was treated successfully using lepirudin for anticoagulation of cardiopulmonary bypass (CPB) and during the postoperative course. "
09/01/2014 - "Normal high density lipoprotein (HDL) protects vascular function; however these protective effects of HDL may absent in valvular heart disease (VHD). "
09/01/2014 - "High density lipoprotein from patients with valvular heart disease uncouples endothelial nitric oxide synthase."
03/01/1988 - "Adipose tissue was obtained at thoracotomy in five control patients with valvular heart disease, all of whom were free of coronary artery disease and all of whom were normolipidemic with normal low density lipoprotein apolipoprotein B levels, and eight patients with coronary artery disease, all of whom had hyperapobetalipoproteinemia. "
08/01/1991 - "Exclusion criteria were unstable angina pectoris, left main coronary artery stenosis greater than 25% luminal diameter reduction, severely depressed left ventricular ejection fraction (less than 35%), significant valvular heart disease, insulin-dependent diabetes mellitus, primary hypercholesterolemia (type II hyperlipoproteinemia, low-density lipoprotein greater than 210 mg/dl), and conditions precluding regular physical exercise. "
|8.||Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA
06/01/1999 - "According to these guidelines, all heart failure patients regardless of etiology (with rare exceptions such as obstructive valvular heart disease) should be treated with an angiotensin-converting enzyme (ACE) inhibitor as first-line treatment of the heart failure. "
06/01/2013 - "Patients with an ALT in the highest quartile were more likely to present with hypotension and a low pulse pressure, to have electrocardiographic evidence of left ventricular dyssynchrony and echocardiographic findings including increased left ventricular dimensions, reduced left ventricular ejection fraction, and valvular heart disease, to require inotropic or vasopressor support during hospitalization, and to report lower β-blocker and angiotensin-converting enzyme inhibitor utilization. "
03/01/2005 - "We studied patients with valvular heart disease to investigate whether chronic preoperative treatment with angiotensin-converting enzyme (ACE) inhibitors modulates the effect of phenylephrine (PE) on anaesthesia-induced hypotension. "
03/01/1992 - "In valvular heart disease, a decrease in myocardial perfusion associated with enlargement of the left ventricle appeared, while in dilated cardiomyopathy, there was a marked decrease in LVEF in proportion to the thallium defect. "
03/01/1981 - "Etiology of abnormal interventricular septal motion detected by M-mode echocardiography after heart valve replacement was studied by two-dimensional echocardiography and thallium 201 scintigraphy in three patients with valvular heart disease (two with mitral regurgitation, and one with aortic regurgitation). "
|10.||Nitroglycerin (Dynamite)FDA LinkGeneric
02/01/1978 - "Nitroglycerin-induced improvement in exercise tolerance and hemodynamics in patients with chronic rheumatic heart valve disease."
02/01/1978 - "Thus, nitroglycerin appears to increase exericse tolerance and improve the hemodynamic response to exercise in patients with heart valve disease and may be valuable in the long-term pharmacologic therapy of such patients."
02/01/1978 - "To determine whether nitroglycerin may prove effective therapeutically in ambulatory patients with heart valve disease, its effects on hemodynamics and exercise capacity were studied in 11 severely symptomatic adults who were already receiving optimal treatment with digitalis and diuretic agents. "
11/01/1980 - "The combined and separate hemodynamic effects of dobutamine and IV nitroglycerin were compared in 12 patients with chronic congestive heart failure (nine with ischemic heart disease, two with idiopathic congestive cardiomyopathy, and one with valvular heart disease). "
|1.||Surgical Instruments (Clip)
04/01/2015 - "Transcatheter procedures have been adopted as novel treatment strategy for patients with valvular heart disease, particularly for those who are inoperable or at high risk for surgical valve procedures. "
02/01/2006 - "Up to now the gold standard for the treatment of heart valve disease is still open surgical valve repair and replacement. "
10/01/2012 - "Surgical valve replacement represents the treatment of choice for symptomatic and severe valvular heart disease. "
11/01/2006 - "Surgical valve replacement is the treatment of choice in patients with severe valvular heart disease. "
09/01/2011 - "Degenerative aortic stenosis (AS) has become the most common valvular heart disease and the definitive treatment of symptomatic, severe AS is surgical valve replacement. "
10/01/2013 - "In patients with long-standing persistent AF and valvular heart disease, the hybrid approach with surgical cryoablation consisting of pulmonary veins isolation and left atrial linear lesions combined with transcatheter radiofrequency ablation was highly effective in maintaining SR for a very long-term follow-up. "
07/01/2000 - "Linear cryoablation with lesions connecting the four pulmonary veins and the mitral annulus is effective in restoration and maintenance of SR in patients with heart valve disease and chronic AF. "
10/01/2013 - "From 2000 to 2002, 33 patients with long-standing persistent AF and valvular heart disease underwent valve surgery and cryoablation (pulmonary veins isolation and mitral isthmus and roof line lesions). "
01/01/2011 - "We evaluated medium-term results of the left-sided maze procedure using cryoablation in patients with valvular heart disease. "
07/01/2000 - "We sought to evaluate whether a limited surgical cryoablation of the posterior region of the left atrium was safe and effective in the cure of atrial fibrillation (AF) in patients with associated valvular heart disease. "
|3.||Cardiopulmonary Bypass (Heart-Lung Bypass)
04/01/2014 - "The aim of this study was to test the hypothesis that normothermic cardiopulmonary bypass (CPB) is as effective as hypothermic CPB in terms of cardiac protection (cTnI level) and outcome in patients with valvular heart disease. "
03/01/2013 - "The study aim was to detect the most sensitive nutritional screening tool and to assess its prognostic value with regards to an adverse clinical course in patients with heart valve disease undergoing cardiopulmonary bypass (CPB). "
02/01/2011 - "This study was conducted to evaluate the effect of a new ultrafiltration technique--the subzero-balanced ultrafiltration (SBUF)--on lung gas exchange capacity after cardiopulmonary bypass (CPB) in adult patients with heart valve disease. "
04/01/2015 - "To share our experience highlighting the additional use of cardiopulmonary bypass (CPB) in cases other than the conventional ischemic, congenital and valvular heart diseases. "
04/01/2014 - "Hypothermic versus normothermic cardiopulmonary bypass in patients with valvular heart disease."
|4.||Prostheses and Implants (Prosthesis)
09/01/1994 - "Analysis of the first 1000 examinations performed on hospitalized patients and outpatients, in most cases to study either native valvular heart disease and valvular prosthesis or to search for embolic sources. "
07/01/2015 - "Valvular heart disease as the main diagnosis (including valvular prosthesis) accounted for 22.8% of the cases. "
01/01/2015 - "Heart valve diseases are usually treated by surgical intervention addressed for the replacement of the damaged valve with a biosynthetic or mechanical prosthesis. "
03/01/2010 - "Surgical replacement of a native valve with a biological or mechanical prosthesis is the definitive treatment for many forms of advanced valvular heart disease. "
04/01/2007 - "Optimal matching of prosthesis to patient is a clinical challenge for all caretakers involved in the treatment of valvular heart disease; this review provides guidelines to identify those patients who will benefit most from the Ross procedure, and those for whom it is inadvisable."
11/01/2015 - "Similarly, catheter-based approaches for the treatment of other valve lesions in patients with congenital valve disease are gaining interest, based in large part on promising evidence from studies of patients with acquired adult valvular heart disease."
12/01/2014 - "Coronary and valvular heart disease are treated increasingly by less invasive percutaneous catheter based procedures instead of open-heart surgery. "
09/01/2014 - "Valvular heart disease is an example of an age-related health problem with rising prevalence that has recently seen an emergence of new catheter-based technologies, which are rapidly changing the treatment landscape. "
02/01/2014 - "The Year in Cardiology 2013: valvular heart disease (focus on catheter-based interventions)."
09/01/2007 - "Catheter-based modification of heart valve diseases: from experimental to clinical application."